Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Mar 1;20(2):165-171.
doi: 10.1097/COH.0000000000000907. Epub 2025 Jan 17.

Persistent elite controllers as the key model to identify permanent HIV remission

Affiliations
Review

Persistent elite controllers as the key model to identify permanent HIV remission

Carmen Gasca-Capote et al. Curr Opin HIV AIDS. .

Abstract

Purpose of review: To summarize the heterogeneity in the elite controllers population with the aim to identify a compatible profile with a persistent HIV remission, making distinction between persistent elite controllers, people with HIV (PWHIV) who permanently maintain virological control in the absence of antiretroviral treatment (ART), and transient elite controllers, PWHIV who eventually lose virological control. For this purpose, it is important to consider the mechanisms and biomarkers that have previously been associated with the maintenance and loss of the natural virological control.

Recent findings: Transient elite controllers, before losing virological control, exhibit a distinct metabolomic, proteomic, microRNAs (miRNA), immunological and virological profile compared to persistent elite controllers. In addition to a reduced and less polyfunctional HIV-specific T-cell response, transient elite controllers show a greater proportion of intact proviruses integrated into genic regions. In contrast, persistent elite controllers display a privileged HIV-1 reservoir profile with absence of detected intact proviruses or low proportion of clonal intact proviruses preferentially integrated into genomic features associated with HIV-1 transcriptional repression.

Summary: According to previous studies, the comprehensive characterization of persistent elite controllers might be crucial to identify other PWHIV with this distinct profile as spontaneously cured.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Box 1
Box 1
no caption available
FIGURE 1
FIGURE 1
Persistent controllers as the key model to identify permanent HIV remission. Schematic diagram of different mechanisms associated to the maintenance and loss of the virological control.

Similar articles

  • Factors Leading to the Loss of Natural Elite Control of HIV-1 Infection.
    Pernas M, Tarancón-Diez L, Rodríguez-Gallego E, Gómez J, Prado JG, Casado C, Dominguez-Molina B, Olivares I, Coiras M, León A, Rodriguez C, Benito JM, Rallón N, Plana M, Martinez-Madrid O, Dapena M, Iribarren JA, Del Romero J, García F, Alcamí J, Muñoz-Fernández M, Vidal F, Leal M, Lopez-Galindez C, Ruiz-Mateos E. Pernas M, et al. J Virol. 2018 Feb 12;92(5):e01805-17. doi: 10.1128/JVI.01805-17. Print 2018 Mar 1. J Virol. 2018. PMID: 29212942 Free PMC article.
  • HIV Proviral Burden, Genetic Diversity, and Dynamics in Viremic Controllers Who Subsequently Initiated Suppressive Antiretroviral Therapy.
    Omondi FH, Sudderuddin H, Shahid A, Kinloch NN, Jones BR, Miller RL, Tsai O, MacMillan D, Trocha A, Brockman MA, Brumme CJ, Joy JB, Liang R, Walker BD, Brumme ZL. Omondi FH, et al. mBio. 2021 Dec 21;12(6):e0249021. doi: 10.1128/mBio.02490-21. Epub 2021 Nov 16. mBio. 2021. PMID: 34781741 Free PMC article.
  • The HIV-1 reservoir landscape in persistent elite controllers and transient elite controllers.
    Gasca-Capote C, Lian X, Gao C, Roseto IC, Jiménez-León MR, Gladkov G, Camacho-Sojo MI, Pérez-Gómez A, Gallego I, Lopez-Cortes LE, Bachiller S, Vitalle J, Rafii-El-Idrissi Benhnia M, Ostos FJ, Collado-Romacho AR, Santos J, Palacios R, Gomez-Ayerbe C, Muñoz-Medina L, Ruiz-Sancho A, Frias M, Rivero-Juarez A, Roca-Oporto C, Hidalgo-Tenorio C, Rull A, Olalla J, Lopez-Ruz MA, Vidal F, Viladés C, Mastrangelo A, Cavassini M, Espinosa N, Perreau M, Peraire J, Rivero A, López-Cortes LF, Lichterfeld M, Yu XG, Ruiz-Mateos E. Gasca-Capote C, et al. J Clin Invest. 2024 Feb 20;134(8):e174215. doi: 10.1172/JCI174215. J Clin Invest. 2024. PMID: 38376918 Free PMC article.
  • Elite and posttreatment controllers, two facets of HIV control.
    Mastrangelo A, Banga R, Perreau M. Mastrangelo A, et al. Curr Opin HIV AIDS. 2022 Sep 1;17(5):325-332. doi: 10.1097/COH.0000000000000751. Epub 2022 Jul 25. Curr Opin HIV AIDS. 2022. PMID: 35938466 Free PMC article. Review.
  • Immunological effector mechanisms in HIV-1 elite controllers.
    Hartana CA, Yu XG. Hartana CA, et al. Curr Opin HIV AIDS. 2021 Sep 1;16(5):243-248. doi: 10.1097/COH.0000000000000693. Curr Opin HIV AIDS. 2021. PMID: 34270465 Free PMC article. Review.

Cited by

References

    1. Eisele E, Siliciano RF. Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity 2012; 37:377–388. - PMC - PubMed
    1. Jarrin I, Rava M, Del Romero Raposo J, et al. . Life expectancy of people with HIV on antiretroviral therapy in Spain. AIDS 2024; 38:387–395. - PubMed
    1. Crowell TA, Gebo KA, Blankson JN, et al. . Hospitalization rates and reasons among HIV elite controllers and persons with medically controlled HIV infection. J Infect Dis 2015; 211:1692–1702. - PMC - PubMed
    1. Dominguez-Molina B, Leon A, Rodriguez C, et al. . Analysis of non-AIDS-defining events in HIV controllers. Clin Infect Dis 2016; 62:1304–1309. - PubMed
    1. Leon A, Perez I, Ruiz-Mateos E, et al. . Rate and predictors of progression in elite and viremic HIV-1 controllers. AIDS 2016; 30:1209–1220. - PubMed